RxDoctor Payments Data

Brian Murrell, MD

Interventional Pain Medicine · Amarillo, TXNPI 1003805946

Payments from drug & device makers

$1,671in general payments, 2019–2025

Across 136 payments — averaging $12.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$125
  • Amgen$111
  • Medtronic$37
  • Collegium Pharmaceutical, Inc.$30
  • Arbor Pharmaceuticals, Inc.$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$1,671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott126$1,322
Boston Scientific2$125
Amgen1$111
Medtronic2$37
Collegium Pharmaceutical, Inc.2$30
Arbor Pharmaceuticals, Inc.1$17
Si-bone, Inc.1$15
Companion Medical, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,671 in reported general payments places this provider in the 20th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$68,545
Medicare patients
71
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl16$33,695
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen889$33,148
Xtampza ErOxycodone Myristate25$19,006
Fentanyl74$6,057
Oxycodone Hcl375$6,017
Morphine Sulfate ErMorphine Sulfate127$4,334
Buprenorphine13$4,074
Gabapentin262$3,312
Pregabalin225$2,592
Tizanidine Hcl304$2,556
Oxymorphone Hcl ErOxymorphone Hcl14$2,484
Lidocaine33$2,473
Morphine Sulfate37$1,978
Acetaminophen-CodeineAcetaminophen With Codeine59$1,233
Baclofen90$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$30$19,00625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →